Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

John W. Eikelboom, Stuart J. Connolly, Jackie Bosch, Gilles R. Dagenais, Robert G. Hart, Olga Shestakovska, Rafael Diaz, Marco Alings, Eva M. Lonn, Sonia S. Anand, Petr Widimsky, Masatsugu Hori, Alvaro Avezum, Leopoldo S. Piegas, Kelley R.H. Branch, Jeffrey Probstfield, Deepak L. Bhatt, Jun Zhu, Yan Liang, Aldo P. MaggioniPatricio Lopez-Jaramillo, Martin O’Donnell, Ajay Kakkar, Keith A.A. Fox, Alexander N. Parkhomenko, Georg Ertl, Stefan Störk, Matyas Keltai, Lars Ryden, Nana Pogosova, Antonio L. Dans, Fernando Lanas, Patrick J. Commerford, Christian Torp-Pedersen, Tomek J. Guzik, Peter B. Verhamme, Dragos Vinereanu, Jae-Hyung Kim, Andrew M. Tonkin, Basil S. Lewis, Camilo Felix, Khalid Yusoff, P. Gabriel Steg, Kaj P. Metsarinne, Nancy Cook Bruns, Frank Misselwitz, Edmond Chen, Darryl Leong, Salim Yusuf, Joseph Selvanayagam

Research output: Chapter in Book/Report/Conference proceedingChapter

691 Citations (Scopus)

Abstract

BackgroundWe evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. MethodsIn this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. ResultsThe primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P
Original languageEnglish
Title of host publicationNew England Journal of Medicine
PagesNEJMoa1709118
DOIs
Publication statusPublished - 27 Aug 2017

Publication series

NameNew England Journal of Medicine

Cite this

Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., ... Selvanayagam, J. (2017). Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. In New England Journal of Medicine (pp. NEJMoa1709118). (New England Journal of Medicine). https://doi.org/10.1056/NEJMoa1709118